Caribou Biosciences’ (CRBU) “Neutral” Rating Reaffirmed at HC Wainwright

Caribou Biosciences (NASDAQ:CRBU)‘s stock had its “neutral” rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Thursday, MarketBeat reports.

Several other equities analysts have also recently commented on the stock. Royal Bank Of Canada cut shares of Caribou Biosciences from an “outperform” rating to a “sector perform” rating and set a $1.00 price target for the company. in a research report on Wednesday. Leerink Partners reiterated a “market perform” rating and issued a $1.00 target price (down from $4.00) on shares of Caribou Biosciences in a report on Wednesday. Bank of America lowered their target price on Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Wall Street Zen downgraded Caribou Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, September 19th. Finally, Brookline Capital Markets cut Caribou Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $5.50.

Caribou Biosciences Price Performance

NASDAQ CRBU opened at $0.62 on Thursday. The company has a market cap of $66.19 million, a P/E ratio of -0.57 and a beta of 2.31. The stock has a 50-day moving average of $1.45 and a two-hundred day moving average of $1.75. Caribou Biosciences has a 1-year low of $0.55 and a 1-year high of $3.54.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.08. Caribou Biosciences had a negative net margin of 1,030.42% and a negative return on equity of 89.11%. The business had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $2.28 million. On average, analysts anticipate that Caribou Biosciences will post -0.88 EPS for the current fiscal year.

Hedge Funds Weigh In On Caribou Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. CTC Alternative Strategies Ltd. purchased a new position in Caribou Biosciences in the first quarter valued at approximately $29,000. Next Capital Management LLC purchased a new position in Caribou Biosciences during the 2nd quarter worth approximately $35,000. Westmount Partners LLC acquired a new position in Caribou Biosciences during the first quarter worth approximately $37,000. The Manufacturers Life Insurance Company purchased a new stake in Caribou Biosciences in the second quarter valued at approximately $41,000. Finally, Spark Investment Management LLC acquired a new stake in shares of Caribou Biosciences in the second quarter valued at approximately $42,000. 77.51% of the stock is owned by institutional investors and hedge funds.

Caribou Biosciences News Roundup

Here are the key news stories impacting Caribou Biosciences this week:

• Positive Sentiment: Caribou is evaluating strategic alternatives intended to maximize stockholder value. A sale, merger or other transaction could potentially provide value beyond the company’s standalone prospects, although there is no assurance that a transaction will occur. Caribou Biosciences to Evaluate Strategic Alternatives
• Neutral Sentiment: Leerink Partners downgraded CRBU from “outperform” to “market perform” but assigned a $1.00 price target, which remains above the stock’s recent $0.62 reference price. Brookline Capital Markets also maintained a “hold” rating. Leerink Partners Downgrades Caribou Biosciences
• Negative Sentiment: The company plans to halt two key CAR-T programs and cut its workforce, materially reducing its clinical pipeline and future growth prospects. The decision followed challenges in advancing its off-the-shelf cell-therapy strategy and was the primary catalyst for the recent selloff. Caribou Biosciences To Halt Two CAR-T Programs
• Negative Sentiment: RBC downgraded Caribou from “outperform” to “sector perform” and slashed its price target from $10 to $1 while retaining a speculative-risk designation. The downgrade reflects reduced confidence in the company’s development pipeline and heightened uncertainty surrounding the strategic review. RBC Downgrades Caribou Biosciences
• Negative Sentiment: Investor reaction has been sharply negative, with reports describing a roughly 40% or greater plunge in the shares following the program cancellations. CRBU remains an unprofitable biotechnology company, increasing its dependence on a successful strategic transaction or future pipeline restart. Caribou Shares Fall After Plans to Evaluate Strategic Alternatives

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses its proprietary CRISPR-based chRDNA genome-editing platform to engineer immune cells, with an emphasis on allogeneic, or “off-the-shelf,” CAR-T therapies designed to target tumors without requiring cells to be collected from each individual patient.

Caribou’s research and development programs have focused primarily on hematologic malignancies, including investigational CAR-T candidates directed at targets such as CD19 and BCMA.